Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib +/- Bevacizumab as Neoadjuvant Therapy in Advanced Ovarian Cancer
NCT06735326Phase 2Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Nov 2024
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fluzoparib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (3 arms), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Objective Response Rate. Started Nov 2024; status: recruiting.
02
Drugs
fluzoparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT06735326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06735326.